Compare Citius Pharmaceuticals Inc (CTXR) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while Tidewater Inc trades at $91.93 (market cap $4.54B). The key difference: Tidewater Inc is far larger — about 226.9× Citius Pharmaceuticals Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TDW | |
|---|---|---|
Market Cap | $20.01M | $4.54B |
Sector | Health | Utilities |
52-Week High | $1.82 | $91.20 |
52-Week Low | $0.48 | $47.29 |
Enterprise Value | $16.23M | $4.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Tidewater (TDW) trades at $90.20, up 0.64% today, with a bullish technical signal driven by moving averages and ADX. Recent Q2 2026 earnings beat estimates (EPS $0.43 vs. $0.32 expected, Zacks Investment Research, 2026-08-03), though quarterly EPS has missed expectations in three of the last four quarters. The company maintains strong profitability with an 18.34% net margin and robust cash flow from operations of $379.11 million in 2025.
Outlook is mixed: bullish technicals and institutional interest support upside, but earnings misses and a high RSI near overbought levels pose risks. Analyst consensus leans hold (57.7%), with valuation metrics like P/E of 18.5 suggesting fair pricing. Key risks include operational costs from Middle East conflicts and revenue volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
